Abstract

ObjectivesTo compare the lung CT volume (CTvol) and pulmonary function tests in an interstitial lung disease (ILD) population. Then to evaluate the CTvol loss between idiopathic pulmonary fibrosis (IPF) and non-IPF and explore a prognostic value of annual CTvol loss in IPF.MethodsWe conducted in an expert center a retrospective study between 2005 and 2018 on consecutive patients with ILD. CTvol was measured automatically using commercial software based on a deep learning algorithm. In the first group, Spearman correlation coefficients (r) between forced vital capacity (FVC), total lung capacity (TLC), and CTvol were calculated. In a second group, annual CTvol loss was calculated using linear regression analysis and compared with the Mann–Whitney test. In a last group of IPF patients, annual CTvol loss was calculated between baseline and 1-year CTs for investigating with the Youden index a prognostic value of major adverse event at 3 years. Univariate and log-rank tests were calculated.ResultsIn total, 560 patients (4610 CTs) were analyzed. For 1171 CTs, CTvol was correlated with FVC (r: 0.86) and TLC (r: 0.84) (p < 0.0001). In 408 patients (3332 CT), median annual CTvol loss was 155.7 mL in IPF versus 50.7 mL in non-IPF (p < 0.0001) over 5.03 years. In 73 IPF patients, a relative annual CTvol loss of 7.9% was associated with major adverse events (log-rank, p < 0.0001) in univariate analysis (p < 0.001).ConclusionsAutomated lung CT volume may be an alternative or a complementary biomarker to pulmonary function tests for the assessment of lung volume loss in ILD.Key Points• There is a good correlation between lung CT volume and forced vital capacity, as well as for with total lung capacity measurements (r of 0.86 and 0.84 respectively, p < 0.0001).• Median annual CT volume loss is significantly higher in patients with idiopathic pulmonary fibrosis than in patients with other fibrotic interstitial lung diseases (155.7 versus 50.7 mL, p < 0.0001).• In idiopathic pulmonary fibrosis, a relative annual CT volume loss higher than 9.4% is associated with a significantly reduced mean survival time at 2.0 years versus 2.8 years (log-rank, p < 0.0001).

Highlights

  • Interstitial lung diseases (ILDs) encompass a heterogeneous group of chronic and fibrotic lung diseases with distinct disease course and prognosis [1]

  • We found that lung CT volume measurement, enabled by an automatic approach based on a deep learning algorithm, correlated strongly with forced vital capacity (FVC) and total lung capacity (TLC)

  • Using longitudinal lung CT volume loss, we found that patients with Idiopathic pulmonary fibrosis (IPF) had a distinct disease course than other ILDs

Read more

Summary

Introduction

Interstitial lung diseases (ILDs) encompass a heterogeneous group of chronic and fibrotic lung diseases with distinct disease course and prognosis [1]. They may be associated with progressive lung volume loss with impaired quality of life, and in advanced stage, respiratory failure. Idiopathic pulmonary fibrosis (IPF), an inexorably progressive disease, is the most severe and lethal among others [2, 3]. FVC has been proposed as a surrogate marker for disease progression and mortality in all ILDs and has been advocated as a primary outcome in major clinical trials in IPF [4–6]. FVC measurement is subject to inherent measurement variability and might be inaccurate in frail patients, advanced disease stages, and subjects with intractable cough [7, 8]. A new feasible, reproducible, and effortless surrogate biomarker is still needed

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.